康宁杰瑞制药-B2024中期报告

（於開曼群島註冊成立的有限公司）股份代號:9966 2101315161829444546485052 AACR CTLA-4 GMP KN035KN035PD-L1 20249 13 GEMGEM C3 MSI-H 20141222KN035 201631651%49% ADC ADC •KN046BsAbPD-L1CTLA-4KN046NSCLC202423NatureCommunicationsCell Reports MedicineNSCLC20249KN046sq NSCLCIIIOSKN046sq NSCLCOSPFSKN046 •KN026HER2 BsAbHER2IIIKN026HER2KN026KN026HER2BCKN026HER2GC/GEJIIIKN026HER2GCGEJCDE •KN035®PD-L1PD-L120241MSI-H/dMMRGlenmarkGlenmarkKN035KN035 •KN019CTLA-4202311IND •JSKN003HER2ADCIKN026HER2NHER2JSKN003HER2JSKN003II/IIIII20244JSKN003IAACRJSKN00320246JSKN003I/IIIASCOJSKN0032.1mg/kg8.4mg/kgJSKN003HER2BC20249 •JSKN033ADCJSKN003KN035BellberryHER220243 •JSKN016ADCHER3TROP2JSKN016JSKN016TROP2HER3I(TOP1i)20243JSKN016IIND20245 175 1526 •20241KN035MSI-HdMMR •20241GlenmarkGlenmarkKN035KN035 •20242KN046BCIIPFSOSNatureCommunications •20243JSKN016CDE •KN046NSCLCII20243Cell ReportsMedicine •20243JSKN033HER2I/II •20244 AACRJSKN003HER2IJSKN003 •20245JSKN016HER3TROP2ADCI •20246 ASCOJSKN003I/IIIJSKN003 •20246ArriVent BioPharma, Inc.(Alphatecan)ADC •20247KN035NDA1,000L2,000L •20249KN046sq NSCLCIIIOSKN046sq NSCLCOSPFSKN046 •JSKN003HER2BC20249 •20207 64,000L (2x2,000L)2022202212 36,000L (3x2,000L)20238II40,000LADC ADC ADC (i)sdAb(ii)sdAbCRIBCRAMBADCADCBADDCCIMC(iii)FDAGMP40,000L 202111KN035®KN046KN0262025NDA 18A.08(3)KN046KN026 ADC 20246 30173.620236 30136.530.8202363033.2202463039.8202363043.020246 307.320236 3048.820246 3044.620236 3040.42024630194.520236 30194.7202463034.6202363033.220246305.620236 307.0 20246 30173.6(i)(ii)(iii) 202463090.62023630117.020162KN03520246 30KN03569.8202363071.5202463020.820236 3045.5202112KN035 2024630KN035416,0002023630309,000202111KN035 202463078.220236307.2202420241 2520246 5 20246 304.320236 3011.9 202463030.8202363033.2 202463039.8202363043.020236 3037.7202463030.320236 305.220246 309.42024 20246 307.320236 3048.8 (i)(ii)(iii)(iv)(v) 20246302023630194.7194.5 202463034.6202363033.2 (i)(ii)(iii) 20236 307.020246 305.6(i)(ii) 20246303,547.520236302,990.4 202420236 30 20236 3039.95.020246 3044.9 202312 31550.130.12024630520.0 16 20246302023123126.927.1 2023123178.713.5202463065.2 20246 3013.2202312 317.12024 (i)(ii)(iii) 2023123166.56.520246 3060.0 (i)(ii) 202312311,086.020246 301,140.2202312 31321.220246 30316.4 202312 31175.120246 30161.8(i)(ii) 202312 314.420246300.9 202312317.120246306.6 20231231202463025.524.0KN03512.5KN02610.74.35%3.70%KN035KN026KN035KN035KN026 2024630 2024 20246 30320.0202312 31250.02.50%2.87%20246 30243.120.4 (1)(2)(3)100% 2024630 20246 30 20246 30243.120.4 2024630 20246 3020246 302024630 20246304292023630437202463086.820236 3085.3 D.20245 21 20246 30XV352 (1)RubymabRubymabSouth Dakota Trust(2)(3)20246 30964,923,807(L) (1)(2)20246 30964,923,807(L) 2024630 20246 30336 (1)RubymabSouth Dakota Trust(2)Sky DiamondSky Diamond(3)PearlmedPearlmed(4)20246 30964,923,807(L) 20246 30336 202463018 20246 3020246 30 20246 3020246 30 201832820191212 2024630C.2.1C.2.1 2024630 202412 31 13.51B(1) 20246 30•2410 20246 3020236 30 2024521(i)(ii)(iii)20231 1 202461220247 16 17 (1) (2)4.81 20205 2520246 1220245 21 1,180,000120,000 (1)14A.06 (2)(a)20224231,451,000(b)2023 4 231,451,000(c)2024 4 231,451,000(d)20254231,852,000(e)2026 4231,400,000(f)2027 4231,400,000 (3)(a)20221025120,000(b)20231025120,000(c)20241025120,000(d)202510 25240,000 (4)(a)2023 425400,000(b)2024 425400,000(c)2025 425400,000(d)2026425800,000 (5)(a)2023102444,000(b)2024 102444,000(c)2025102444,000(d)2026102488,000 (6)(a)20241024100,000(b)20251024100,000(c)20261024100,000(d)202710 24200,000 (7)(a)2025423236,000(b)2026 423236,000(c)2027423236,000(d)2028423472,000 4.170 44,733,26943,673,269 18 20213 2320246 1220245 21 130,000 (1)14A.06(2)(a)20%2022423(b)20%2023423(c)20%2024423(d)40%20254 23(3)(a)20%202210 23(b)20%202310 23(c)20%202410 23(d)40%202510 23(4)(a)20%2023425(b)20%2024425(c)20%2025425(d)40%20264 25(5)(a)20%202310 24(b)20%202410 24(c)20%202510 24(d)40%202610 24(6)(a)26,0002025423(b)26,0002026423(c)26,0002027423(d)52,00020284 234.170(7)4.410(8)20231231320,026(a)67,03720234 23(b)144,000202310 23(c)98,00020234 25(d)10,9892023102412.782023 11,887,35911,914,396 18 56,620,62855,587,66596,492,38020246 1210%95,433,7721,058,608 0.14% 201912 122,042.520246301,888.4 KN046 KN026 2024 20232Rubymab15.2215.0525,000,00050376.220232 316.1420232320232 9202463039.4 ADC 50.0100.013.3%26.6%202412312025 202481520246 1250.02024815 2024815 45722024630343434 2410 34 • 20248 15 20246 30 20246 30 (i)201841820195 20246 30 1. 2018328201912 12 34D2 2. 202463020231231 20241 1 161177 20246 30 2. 3. (i) 3. (i) 10% (ii) (a) 3. (ii) (a) • • (b) 30 3. (ii) (c) 20246 301215 4. 2,984,00020236301,232,0006,462,00020236304,017,000 5. 20246 30 6. 7. 25%202325%202210182022202415% 201726%202326%Alphamab (Australia) Co. Pty. Ltd.26%202326% 28.25%216.5%16.5% 21% 8. 9. 20246 30 10. 202420236 3018(a)18(b)1718(c) 11.